Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera A Mullally, C Bruedigam, L Poveromo, FH Heidel, A Purdon, T Vu, ... Blood, The Journal of the American Society of Hematology 121 (18), 3692-3702, 2013 | 179 | 2013 |
NK cells require IL-28R for optimal in vivo activity F Souza-Fonseca-Guimaraes, A Young, D Mittal, L Martinet, C Bruedigam, ... Proceedings of the National Academy of Sciences 112 (18), E2376-E2384, 2015 | 93 | 2015 |
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy C Bruedigam, FO Bagger, FH Heidel, CP Kuhn, S Guignes, A Song, ... Cell stem cell 15 (6), 775-790, 2014 | 89 | 2014 |
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias R Thijssen, ST Diepstraten, D Moujalled, E Chew, C Flensburg, MX Shi, ... Blood, The Journal of the American Society of Hematology 137 (20), 2721-2735, 2021 | 86 | 2021 |
Autophagy is required for stem cell mobilization by G-CSF L Leveque-El Mouttie, T Vu, KE Lineburg, RD Kuns, FO Bagger, BE Teal, ... Blood, The Journal of the American Society of Hematology 125 (19), 2933-2936, 2015 | 47 | 2015 |
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations RJ Austin, J Straube, C Bruedigam, G Pali, S Jacquelin, T Vu, J Green, ... Leukemia 34 (4), 1075-1089, 2020 | 43 | 2020 |
EphA2 is a therapy target in EphA2-positive leukemias but is not essential for normal hematopoiesis or leukemia S Charmsaz, K Beckett, FM Smith, C Bruedigam, AS Moore, F Al-Ejeh, ... PloS one 10 (6), e0130692, 2015 | 27 | 2015 |
Telomerase in hematologic malignancies C Bruedigam, SW Lane Current Opinion in Hematology 23 (4), 346-353, 2016 | 18 | 2016 |
Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia T Vu, J Straube, AH Porter, M Bywater, A Song, V Ling, L Cooper, G Pali, ... Nature communications 11 (1), 3021, 2020 | 17 | 2020 |
Acute myeloid leukemia stem cell function is preserved in the absence of autophagy AH Porter, L Leveque-El Mouttie, T Vu, C Bruedigam, J Sutton, ... Haematologica 102 (9), e344, 2017 | 13 | 2017 |
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia VY Ling, J Straube, W Godfrey, R Haldar, Y Janardhanan, L Cooper, ... Leukemia 37 (1), 143-153, 2023 | 12 | 2023 |
Epigenetic activation of plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML JM Salmon, I Todorovski, KL Stanley, C Bruedigam, CJ Kearney, ... Cancer Discovery 12 (6), 1560-1579, 2022 | 12 | 2022 |
Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling T Vu, R Austin, CP Kuhn, C Bruedigam, A Song, S Guignes, S Jacquelin, ... Haematologica 101 (3), e77, 2016 | 9 | 2016 |
Telomerase-targeted therapies in myeloid malignancies JA Waksal, C Bruedigam, RS Komrokji, CHM Jamieson, JO Mascarenhas Blood Advances 7 (16), 4302-4314, 2023 | 7 | 2023 |
The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML-a randomized trial in patient-derived xenografts C Bruedigam, B Wackrow, A Song, AH Porter, SCW Lee, AS Moore, ... Blood 128 (22), 578, 2016 | 5 | 2016 |
Autophagy is required for long-term hematopoietic stem cell (HSC) function and G-CSF-induced HSC mobilization L Leveque, T Vu, RD Kuns, BE Teal, M Lor, KE Lineburg, C Bruedigam, ... Blood, The Journal of the American Society of Hematology 122 (21), 892-892, 2013 | 4 | 2013 |
Oncogenic drivers dictate immune control of acute myeloid leukemia RJ Austin, J Straube, R Halder, Y Janardhanan, C Bruedigam, ... Nature Communications 14 (1), 2155, 2023 | 3 | 2023 |
Imetelstat-Mediated Alterations in Fatty Acid Metabolism To Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia C Bruedigam, AH Porter, A Song, G Vroeg in de Wei, T Stoll, J Straube, ... Nature Cancer, 2023 | 3 | 2023 |
Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia C Bruedigam, AH Porter, A Song, T Stoll, J Straube, LT Cooper, G Cheng, ... Blood 140 (Supplement 1), 487-488, 2022 | 3 | 2022 |
Inhibition of telomerase with imetelstat is detrimental to leukemia stem cells in acute myeloid leukemia (AML) C Bruedigam, FO Bagger, FH Heidel, C Kuhn, S Guignes, A Song, ... Blood 124 (21), 2322, 2014 | 3 | 2014 |